Intellia's Q2 Results Highlight Positive Phase 3 Data and FDA Filing Plans for Gene-Editing Therapy
NTLA sits 35% above its 52-week low of $7.95.
Summary
Intellia reported Q2 2026 financial results alongside key business updates. The company highlighted positive Phase 3 HAELO trial data for lonvo-z in hereditary angioedema, showing an 87% reduction in attacks versus placebo. Enrollment in Phase 3 ATTR trials resumed, and new genomic insights on nex-z's safety were gained. Launch readiness activities advanced, with field teams finalized. Intellia expects FDA acceptance of its BLA for lonvo-z in H2 2026, with a potential commercial launch in H1 2027. This follows the Q1 2026 report where cash runway was extended into 2028, and the June 2026 additional Phase 3 data release. The updates reinforce the company's progress toward a first commercial product and de-risk the pipeline.
At the time of this announcement, NTLA was trading at $10.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $7.95 to $28.25. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.